Animal Models of Osteogenesis Imperfecta - Osteogenesis Imperfecta - page 187

[55] Cassella JP, Ali SY. Abnormal collagen and mineral formation
in osteogenesis imperfecta. Bone Miner 1992;17(2):123-8.
[56] Camacho NP, Landis WJ, Boskey AL. Mineral changes in a mouse
model of osteogenesis imperfecta detected by Fourier transform
infrared microscopy. Connect Tissue Res 1996;35(1-4):259-65.
[57] Fratzl P, Paris O, Klaushofer K, Landis WJ. Bone mineralization
in an osteogenesis imperfecta mouse model studied by small-
angle x-ray scattering. J Clin Invest 1996;97(2):396-402.
[58] Phillips CL, Pfeiffer BJ, Luger AM, Franklin CL. Novel colla-
gen glomerulopathy in a homotrimeric type I collagen mouse
(oim). Kidney Int 2002;62(2):383-91.
[59] Pfeiffer BJ, Franklin CL, Hsieh FH, Bank RA. Phillips CL.
Alpha 2(I) collagen deicient oim mice have altered biome-
chanical integrity, collagen content, and collagen crosslinking
of their thoracic aorta. Matrix Biol 2005;24(7):451-8.
[60] Gentry BA, Ferreira JA, McCambridge AJ, Brown M, Phillips
CL. Skeletal muscle weakness in osteogenesis imperfecta mice.
Matrix Biol 2010;29(7):638-44.
[61] Lopez Franco GE, Huang A, Pleshko Camacho N, Blank RD.
Dental phenotype of the col1a2(oim) mutation: DI is present in
both homozygotes and heterozygotes. Bone 2005;36(6):1039-46.
[62] Lopez Franco GE, Huang A, Pleshko Camacho N, Stone
DS, Blank RD. Increased Young's modulus and hardness of
Col1a2oim dentin. J Dent Res 2006;85(11):1032-6.
[63] Miles CA, Sims TJ, Camacho NP, Bailey AJ. The role of the
alpha2 chain in the stabilization of the collagen type I hetero-
trimer: a study of the type I homotrimer in oim mouse tissues.
J Mol Biol 2002;321(5):797-805.
[64] Kuznetsova N, McBride Jr DJ, Leikin S. Osteogenesis imper-
fecta murine: interaction between type I collagen homotrimers.
J Mol Biol 2001;309(3):807-15.
[65] McBride Jr DJ, Kadler KE, Hojima Y, Prockop DJ. Self-
assembly into ibrils of a homotrimer of type I collagen. Matrix
1992;12(4):256-63.
[66] Nadiarnykh O, Plotnikov S, Mohler WA, Kalajzic I, Redford-
Badwal D, Campagnola PJ. Second harmonic generation imag-
ing microscopy studies of osteogenesis imperfecta. J Biomed
Opt 2007;12(5):051805.
[67] Zhang H, Doty SB, Hughes C, Dempster D, Camacho NP.
Increased resorptive activity and accompanying morphological
alterations in osteoclasts derived from the oim/oim mouse model
of osteogenesis imperfecta. J Cell Biochem 2007;102(4):1011-20.
[68] Li H, Jiang X, Delaney J, et al. Immature osteoblast lineage cells
increase osteoclastogenesis in osteogenesis imperfecta murine.
Am J Pathol 2010;176(5):2405-13.
[69] McBride Jr DJ, Choe V, Shapiro JR, Brodsky B. Altered collagen
structure in mouse tail tendon lacking the alpha 2(I) chain. J
Mol Biol 1997;270(2):275-84.
[70] Weis SM, Emery JL, Becker KD, McBride Jr DJ, Omens JH,
McCulloch AD. Myocardial mechanics and collagen struc-
ture in the osteogenesis imperfecta murine (oim). Circ Res
2000;87(8):663-9.
[71] Vouyouka AG, Pfeiffer BJ, Liem TK, Taylor TA, Mudaliar J,
Phillips CL. The role of type I collagen in aortic wall strength
with a homotrimeric. J Vasc Surg 2001;33(6):1263-70.
[72] Brodeur AC, Wirth DA, Franklin CL, Reneker LW, Miner JH,
Phillips CL. Type I collagen glomerulopathy: postnatal col-
lagen deposition follows glomerular maturation. Kidney Int
2007;71(10):985-93.
[73] Roberts-Pilgrim AM, Makareeva E, Myles MH, et al. Deicient
degradation of homotrimeric type I collagen, alpha1(I)(3) glo-
merulopathy in oim mice. Mol Genet Metab 2011;104(3):373-82.
[74] Vanleene M, Saldanha Z, Cloyd KL, et al. Transplantation of
human fetal blood stem cells in the osteogenesis imperfecta
mouse leads to improvement in multiscale tissue properties.
Blood 2011;117(3):1053-60.

[75] Oyama M, Tatlock A, Fukuta S, et al. Retrovirally transduced bone
marrow stromal cells isolated from a mouse model of human
osteogenesis imperfecta (oim) persist in bone and retain the ability
to form cartilage and bone after extended passaging. Gene Ther
1999;6(3):321-9.
[76] Niyibizi C, Smith P, Mi Z, Phillips CL, Robbins P. Transfer of
proalpha2(I) cDNA into cells of a murine model of human
Osteogenesis Imperfecta restores synthesis of type I collagen
comprised of alpha1(I) and alpha2(I) heterotrimers in vitro and
in vivo. J Cell Biochem 2001;83(1):84-91.
[77] Wang X, Li F, Niyibizi C. Progenitors systemically transplanted
into neonatal mice localize to areas of active bone formation
in vivo: implications of cell therapy for skeletal diseases. Stem
Cells 2006;24(8):1869-78.
[78] Mehrotra M, Rosol M, Ogawa M, Larue AC. Amelioration of a
mouse model of osteogenesis imperfecta with hematopoietic
stem cell transplantation: microcomputed tomography studies.
Exp Hematol 2010;38(7):593-602.
[79] Li F, Wang X, Niyibizi C. Bone marrow stromal cells contribute
to bone formation following infusion into femoral cavities of a
mouse model of osteogenesis imperfecta. Bone 2010;47(3):546-55.
[80] King D, Chase J, Havey RM, et al. Effects of growth hormone
transgene expression on vertebrae in a mouse model of osteo-
genesis imperfecta. Spine 2005;30(13):1491-5.
[81] King D, Jarjoura D, McEwen HA, Askew MJ. Growth hormone
injections improve bone quality in a mouse model of osteogen-
esis imperfecta. J Bone Miner Res 2005;20(6):987-93.
[82] Camacho NP, Raggio CL, Doty SB, et al. A controlled study of
the effects of alendronate in a growing mouse model of osteo-
genesis imperfecta. Calcif Tissue Int 2001;69(2):94-101.
[83] McCarthy EA, Raggio CL, Hossack MD, et al. Alendronate treat-
ment for infants with osteogenesis imperfecta: demonstration of
eficacy in a mouse model. Pediatr Res 2002;52(5):660-70.
[84] Evans KD, Lau ST, Oberbauer AM, Martin RB. Alendronate
affects long bone length and growth plate morphology in
the oim mouse model for Osteogenesis Imperfecta. Bone
2003;32(3):268-74.
[85] Camacho NP, Carroll P, Raggio CL. Fourier transform infrared
imaging spectroscopy (FT-IRIS) of mineralization in bisphospho-
nate-treated oim/oim mice. Calcif Tissue Int 2003;72(5):604-9.
[86] Misof BM, Roschger P, Baldini T, et al. Differential effects of
alendronate treatment on bone from growing osteogenesis
imperfecta and wild-type mouse. Bone 2005;36(1):150-8.
[87] Rao SH, Evans KD, Oberbauer AM, Martin RB.
Bisphosphonate treatment in the oim mouse model alters bone
modeling during growth. J Biomech 2008;41(16):3371-6.
[88] Delos D, Yang X, Ricciardi BF, Myers ER, Bostrom MP,
Camacho NP. The effects of RANKL inhibition on fracture
healing and bone strength in a mouse model of osteogenesis
imperfecta. J Orthop Res 2008;26(2):153-64.
[89] Bargman R, Huang A, Boskey AL, Raggio C, Pleshko N. RANKL
inhibition improves bone properties in a mouse model of osteo-
genesis imperfecta. Connect Tissue Res 2010;51(2):123-31.
[90] Bargman R, Posham R, Boskey AL, DiCarlo E, Raggio C,
Pleshko N. Comparable outcomes in fracture reduction and
bone properties with RANKL inhibition and alendronate treat-
ment in a mouse model of osteogenesis imperfecta. Osteoporos
Int 2012;23(3):1141-50.
[91] Nicholls AC, Osse G, Schloon HG, et al. The clinical features of
homozygous alpha 2(I) collagen deicient osteogenesis imper-
fecta. J Med Genet 1984;21(4):257-62.
[92] Pihlajaniemi T, Dickson LA, Pope FM, et al. Osteogenesis
imperfecta: cloning of a pro-alpha 2(I) collagen gene with a
frameshift mutation. J Biol Chem 1984;259(21):12941-4.
[93] Nicholls AC, Valler D, Wallis S, Pope FM. Homozygosity
for a splice site mutation of the COL1A2 gene yields a